medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2018, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2018; 27 (1)

Update on the treatment of asthma in pediatrics

Llanos GY, Huerta LJG

Language: Spanish
References: 20
Page: 10-17
PDF size: 251.86 Kb.


ABSTRACT

Asthma is one of the most common chronic conditions in children and the most common reason that children are admitted to the hospital, Childhood asthma prevalence worldwide is rising dramatically making it regarded as a major healthcare problem in children. It manifests as recurrent attacks of wheezing, breathlessness, chest tightness, and coughing, particularly at night and in the early morning. These attacks are usually associated with variable airflow obstruction that is often reversible either spontaneously or with treatment. Chronic airway inflammation is caused by the activation of eosinophils, mast cells, lymphocytes and by airway mucosal damage. Modifiable factors including nonadherence to medication, persistent adverse environmental exposures and psychosocial factors often contribute to poor control in these patient. Patients with uncontrolled asthma account for the majority of direct costs attributable to asthma, with disproportionately high numbers of asthma-related physician visits, emergency department care, and hospitalizations. Despite the development of new drugs and the availability of international treatment guidelines, asthma is still poorly controlled; the goal with this article is to provide updated information for the clinical management of asthma in children.


REFERENCES

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. Available in: www.ginasthma.org

  2. Cook J, Beresford F, Fainardi V, Hall P, Housley G, Jamalzadeh A et al. Managing the paediatric patient with refractory asthma: a multidisciplinary approach. J Asthma Allergy. 2017; 10: 17-30.

  3. Castro-Rodriguez JA, Brockmann PE, Marcus CL. Relation between asthma and sleep disordered breathing in children: is the association causal? Paediatr Respir Rev. 2017; 22: 72-75.

  4. Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC et al. Inflammatory and cormorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017; 195 (3): 302-313.

  5. Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017; 92: 251-265.

  6. 6 Zhou H, Dai C, Pan J. Pediatric asthma and food allergy. J Indian J Pediatr. 2017; 84 (8): 585-590.

  7. Wood PR, Kampschmidt JC, Dube PH, Cagle MP, Chaparro P, Ketchum NS et al. Mycoplasma pneumoniae and health outcomes in children with asthma. Ann Allergy Asthma Immunol. 2017; 119 (2): 146-152.e2.

  8. Vasileiou E, Sheikh A, Butler C, El Ferkh K, von Wissmann B, McMenamin J et al. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin Infect Dis. 2017. doi: 10.1093/cid/cix524.

  9. Ibrahim MA, Rateb AE, Galal BO, Mahmoud GT. Predictive value of IL-35 and IL-17 in diagnosis of childhood asthma. Scandinavian. Journal of Clinical and Laboratory Investigation. 2017; 77 (5): 373-378.

  10. Hall SC, Agrawal DK. Vitamin D and bronchial asthma: an overview of data from the past 5 years hall. Clin Ther. 2017; 39 (5): 917-929.

  11. Pollock M, Sinha IP, Hartling L, Rowe BH, Schreiber S, Fernandes RM. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. Allergy. 2017; 72: 183-200.

  12. Zieck SE, George J, Blakeley BA, Welsh L, James S, Ranganathan S et al. Asthma, bones and corticosteroids: Are inhaled corticosteroids associated with fractures in children with asthma? J Paediatr Child Health. 2017; 53 (8): 771-777.

  13. Wang X, Zhou J, Zhao X, Yi X. Montelukast treatment of acute asthma exacerbations in children aged 2 to 5 years: a randomized, double-blind, placebo-controlled trial-pediatric emergency care. 2017. doi: 10.1097/PEC.0000000000001184

  14. Pajno GB, Bernardini R, Peroni D, Arasi S, Martelli A, Landi M et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr. 2017; 43 (1): 13.

  15. James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017; 17 (1): 55-59.

  16. Marfortt DA, Josviack D, Lozano A, Cuestas E, Agüero L4, Castro-Rodriguez JA. Differences between preschoolers with asthma and allergies in urban and rural environments. J Asthma. 2017; 12: 1-7.

  17. Rodríguez RP, Vidal C, Just J, Tabar AI, Sanchez MI, Eberle P et al. The European survey on adverse systemic reactions in allergen immunotherapy (EASSI): a paediatric assessment. Pediatr Allergy Immunol. 2017; 28 (1): 60-70.

  18. Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017; 38 (4): 250-263.

  19. Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. 2017; 5 (4): 909-916.

  20. Tabatabaian F, Ledford DK, Casale TB. Biologic and new therapies in asthma. Immunol Allergy Clin N Am. 2017; 37: 329-343.




2020     |     www.medigraphic.com